SCHEMBL531434

SCHEMBL531434

O=C1OCCN1Cc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 2/20 0.52
FAAH O00519 5/20 0.51
DDB1 Q16531 1/20 0.49
CRBN Q96SW2 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
LTA4H P09960 1/20 0.48
NAAA Q02083 6/20 0.48
KMT2A Q03164 2/20 0.47
POLB P06746 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
MEN1 O00255 1/20 0.47
SIGMAR1 Q99720 1/20 0.45
F2 P00734 1/20 0.44
PLG P00747 1/20 0.44
ELANE P08246 1/20 0.44
CTSG P08311 1/20 0.44
CMA1 P23946 1/20 0.44
CTRC Q99895 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4519506 0.98 GRM2 (0.51) GRM2FAAHDDB1CRBNL3MBTL1
SCHEMBL9016265 0.89 GRM2 (0.56) GRM2FAAHDDB1CRBNL3MBTL1
SCHEMBL16488375 0.84 DDB1 (0.47) FAAHDDB1CRBNL3MBTL1KMT2A
SCHEMBL20695806 0.83 KDM4E (0.44) GRM2FAAHLTA4HNAAAKMT2A
SCHEMBL11706610 0.82 FAAH (0.53) FAAHCYP2D6SIGMAR1
SCHEMBL28498829 0.82 NAAA (0.52) FAAHL3MBTL1NAAAKMT2APOLB
SCHEMBL259624 0.82 GRM2 (0.53) GRM2FAAHLTA4HNAAAPOLB
SCHEMBL5315528 0.82 GRM2 (0.53) GRM2FAAHLTA4HNAAAPOLB
SCHEMBL14002387 0.82 SMN1; SMN2 (0.55) GRM2LTA4HNAAAKMT2APOLB
SCHEMBL5216969 0.82 GRM2 (0.53) GRM2FAAHL3MBTL1LTA4HNAAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 464 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4646405-A1 PROCESS FOR PREPARING AN N-SUBSTITUTED-2-OXAZOLIDINONE Huntsman Petrochemical LLC (US) 2025-11-12 EP claimed
WO-2024147895-A1 PROCESS FOR PREPARING AN N-SUBSTITUTED-2-OXAZOLIDINONE HUNTSMAN PETROCHEMICAL LLC (US) 2024-07-11 WO claimed
US-10092786-B2 Fire extinguishing composition comprising aldoketones compound XI'AN WESTPEACE FIRE TECHNOLOGY CO., LTD. (CN) 2018-10-09 US claimed
US-7612210-B2 Process for selective synthesis of enantiomers of substituted 1-(2-amino-1-phenyl-ethyl)-cyclohexanols WYETH (US) 2009-11-03 US claimed
WO-2008119734-A2 PROCESS FOR THE MANUFACTURE OF ORGANIC COMPOUNDS NOVARTIS AG (CH) 2008-10-09 WO claimed
EP-1957470-A1 PROCESS FOR SELECTIVE SYNTHESIS OF ENANTIOMERS OF SUBSTITUTED 1-(2-AMINO-1-PHENYL-ETHYL)-CYCLOHEXANOLS Wyeth (US) 2008-08-20 EP claimed
US-20070135449-A1 Process for selective synthesis of enantiomers of substituted 1-(2-amino-1-phenyl-ethyl)-cyclohexanols WYETH (US) 2007-06-14 US claimed
WO-2007067501-A1 PROCESS FOR SELECTIVE SYNTHESIS OF ENANTIOMERS OF SUBSTITUTED 1-(2-AMINO-1-PHENYL-ETHYL)-CYCLOHEXANOLS WYETH (US) 2007-06-14 WO claimed
EP-1077926-B1 PROPYLISOPROPYL ACETAMIDE STEREOISOMERS, A METHOD FOR THEIR SYNTHESIS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM YISSUM RES DEV CO (IL) 2005-02-23 EP claimed
US-20030212131-A1 Propylisopropyl acetic acid and propylisopropyl acetamide stereoisomers, a method for their synthesis and pharmaceutical compositions containing them BIALER MEIR (IL) 2003-11-13 US claimed
US-6630602-B1 Racemic propylisopropyl acetic acid and propylisopropyl acetamide and their isomers in their racemic and stereospecific forms, for use in treatment of neurological and psychotic disorders, and affective disorders and to treat YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2003-10-07 US claimed
EP-0966429-B1 VALNOCTAMIDE STEREOISOMERS, A METHOD FOR THEIR SYNTHESIS AND SEPARATION AND USES THEREOF YISSUM RES DEV CO (IL) 2003-06-04 EP claimed
EP-1077926-A1 PROPYLISOPROPYL ACETIC ACID AND PROPYLISOPROPYL ACETAMIDE STEREOISOMERS, A METHOD FOR THEIR SYNTHESIS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2001-02-28 EP claimed
EP-0966429-A1 VALNOCTAMIDE STEREOISOMERS, A METHOD FOR THEIR SYNTHESIS AND SEPARATION AND USES THEREOF YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 1999-12-29 EP claimed
WO-1999054282-A1 PROPYLISOPROPYL ACETIC ACID AND PROPYLISOPROPYL ACETAMIDE STEREOISOMERS, A METHOD FOR THEIR SYNTHESIS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY (IL) 1999-10-28 WO claimed
WO-1998030536-A1 VALNOCTAMIDE STEREOISOMERS, A METHOD FOR THEIR SYNTHESIS AND SEPARATION AND USES THEREOF YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 1998-07-16 WO claimed
EP-0594608-B1 CHIRAL CATALYSTS FOR ENANTIOSELECTIVE SYNTHESIS RES CORP TECHNOLOGIES INC (US) 1997-10-15 EP claimed
EP-0594608-A1 CHIRAL CATALYSTS FOR ENANTIOSELECTIVE SYNTHESIS. RES CORP TECHNOLOGIES INC (US) 1994-05-04 EP claimed
EP-0594608-A4 CHIRAL CATALYSTS FOR ENANTIOSELECTIVE SYNTHESIS. RES CORP TECHNOLOGIES INC (US) 1993-03-15 EP claimed
WO-1991014672-A1 CHIRAL CATALYSTS FOR ENANTIOSELECTIVE SYNTHESIS RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1991-10-03 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212131-A1 Propylisopropyl acetic acid and propylisopropyl acetamide stereoisomers, a method for their synthesis and pharmaceutical compositions containing them ADCYAP1R1, GRIN2A, PTGER1 GRM2 87/4885FAAH 63/4885DDB1 3515/4885
US-20070135449-A1 Process for selective synthesis of enantiomers of substituted 1-(2-amino-1-phenyl-ethyl)-cyclohexanols MAP2K4, MAP2K1, MAP2K6 GRM2 2477/4885FAAH 1081/4885DDB1 4158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.